令和1年度

巻頭言

令和1年度
ライフサイエンス研究所紀要発刊によせて
研究所長
伊木　雅之（公衆衛生学教室教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、兼任の状態にあることから、医学部の研究に寄与するところが大きな施設となっています。
　私立大学医学部や私立医科大学では、基礎的な研究に専念する医学部出身者は元来多くありませんが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけています。
　このように、人も時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことであります。基礎系および臨床系の研究者の多大な御尽力と、それを支えている研究所の技術員の奮闘に敬意を表するとともに、引き続いてのご協力をお願いする次第です。

令和1年度ライフサイエンス研究所紀要

免疫学教室　（宮澤　正顯　教授）

1. Hakata, Y., H. Michiue, T. Ohtsuki, M. Miyazawa, and M. Kitamatsu.
   A leucine zipper-based peptide hybrid delivers functional Nanog protein inside the cell nucleus. Bioorg. Med. Chem. Let. 29:878-881, 2019.
2. 塚本徹雄, 河原佐智代, 宮澤正顯.
   フレンドウイルス感染マウスにおける白血病発症機構. Bio Clinica 34: 43-49, 2019.
   
3. Takamura, S., S. Kato, C. Motozono, T. Shimaoka, S. Ueha, K. Matsuo, K. Miyauchi, T. Masumoto, A. Katsushima, T. Nakayama, M. Tomura, K. Matsushima, M. Kubo, and M. Miyazawa.
   Interstitial-resident memory CD8+ T cells sustain frontline epithelial memory in the lung. J. Exp. Med. 216: 2736-2747, 2019.
4. Haratani, K., K. Yonesaka, S. Takamura, O. Maenishi, R. Kato, N. Takegawa, H. Kawakami, K. Tanaka, H. Hayashi, M. Takeda, N. Maeda, T. Kagari, K. Hirotani, J. Tsurutani, K. Nishio, K. Doi, M. Miyazawa and K.
   Nakagawa.
   U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J. Clin. Invest. 130:374-388, 2019
5. Hakata, Y., J. Li, T. Fujino, Y. Tanaka, R. Shimizu, and M. Miyazawa.
   Mouse APOBEC3 interferes with autocatalytic cleavage of murine leukemia virus Pr180gag-pol precursor and inhibits Pr65gag processing. PLoS Pathogens 15: e1008173, 2019.
6. Hakata, Y., S. Ishikawa, T. Ohtsuki, M. Miyazawa and M. Kitamatsu.
   Intracellular delivery of a peptide nucleic acid-based hybrid of an autophagy-inducing peptide with a cell-penetrating peptide. Organic & Biomolecular Chemistry 18 :1978-1986, 2020.

解剖学教室　（重吉　康史　教授）

1. Effect of expression alteration in flanking genes on phenotypes of St8sia2-deficient mice
2. Slow shift of dead zone after an abrupt shift of the light-dark cycle

生理学教室　（稲瀨　正彦　教授）

1. Locomotor kinematics and EMG activity during quadrupedal versus bipedal gait in Japanese macaque

ゲノム生物学教室　（西尾　和人　教授）

1. Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M
   Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki De Velasco MA, Kura Y, Sakai K et al.
   Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. JCI Insight 2019; 4.
2. Haratani K, Hayashi H, Takahama T et al.
   Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 2019; 7: 251.
3. Iwahashi N, Sakai K, Noguchi T et al.
   Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing. Sci Rep 2019; 9: 10426.
   
4. Kitazono S, Sakai K, Yanagitani N et al.
   Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer Sci 2019; 110: 3350-3357.
5. Kunimasa K, Nakamura H, Sakai K et al.
   Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer 2019; 132: 59-64.
6. Nakagawa K, Garon EB, Seto T et al.
   Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind,
   placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 1655-1669.
7. Otsubo K, Sakai K, Takeshita M et al.
   Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Oncologist 2019; 24: 1022-1026.
8. Sakai K, Ohira T, Matsubayashi J et al.
   Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens. Cancer Sci 2019; 110: 2044-2049.
9. Sakai K, Takeda M, Shimizu S et al.
   A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Sci Rep 2019; 9: 11340.
10. Takeda M, Sakai K, Nishio K, Nakagawa K.
    Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed. Onco Targets Ther 2019; 12: 5355-5358.
11. Takeda M, Sakai K, Takahama T et al.
    New Era for Next-Generation Sequencing in Japan. Cancers (Basel) 2019; 11.
12. Watanabe S, Otani T, Iwasa T et al.
    A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS. Clin Breast Cancer 2019; 19: e589-e592.
13. Yonesaka K, Iwama E, Hayashi H et al.
    Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Sci Rep 2019; 9: 19501.
14. Yonesaka K, Tanaka K, Kitano M et al.
    Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis 2019; 8: 54.
15. Haratani K, Yonesaka K, Takamura S et al.
    U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest 2020; 130: 374-388.
16. Ishii H, Azuma K, Sakai K et al.
    Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by
    CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. Sci Rep 2020; 10: 691.
17. Iwama E, Sakai K, Hidaka N et al.
    Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2020; 126: 219-227.
18. Noguchi T, Sakai K, Iwahashi N et al.
    Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. Oncol Lett 2020; 19: 2713-2720.
19. Sakai K, Kuwana M, Tanaka H et al.
    HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood 2020.
20. Takahama T, Azuma K, Shimokawa M et al.
    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer 2020; 126: 1940-1948.
21. Takaya H, Nakai H, Sakai K et al.
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecol Oncol 2020; 156: 415-422.
22. Takeda M, Sakai K, Hayashi H et al.
    Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Lung Cancer 2020; 139: 28-34.
    

臨床研究センター　（福岡　和也　教授）

【論文】

1. Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K.
   New era for next-generation sequencing in Japan. Cancers (Basel). 2019 May 28;11(6). pii: E742. doi: 10.3390/cancers11060742.
2. 福岡和也.
   悪性胸膜中皮腫におけるメソテリンの有用性. 呼吸器内科 2019; 36 (1): 69-74.